Update on UCERIS from the JMP Conference (Transcript)

Here's some of what they mentioned...

"We think that there could be some potential to look to add maybe additional 20 to 40 reps if we see that the doctors - once-a-week are getting much better prescription growth. So it's something we'll do analysis over the next six months and probably make a decision at near the end of the year on whether or not it would make sense to add any additional reps to continue to drive UCERIS sales even higher. I mentioned UCERIS was approved in January, mid January of this year, we launched it mid February. We reported 6.6 million of sales in the first quarter What we said is we loaded the pipeline with about $3 million worth of product, a little bit different than maybe a traditional launch and that this product, for a bottle of UCERIS is a little over $1,200. Pretty much no retail pharmacist will put this on the shelf unless they have a prescription. So when we say, we loaded the pipeline it really is just the wholesalers and their distribution centers."

You can read the rest at http://www.earningsimpact.com/Transcript/82102/SNTS/Santarus,-Inc----JMP-Securities-2013-Healthcare-Conference